Then, to confirm this panel, we assessed the differential expression of lncRNA [SBF2-AS1 (SET binding factor 2 antisense RNA1) and FENDRR-19 (Fetal-lethal non-coding developmental regulatory RNA)] and mRNA [NLRP3 (NOD-like receptor and pyrin domain-containing 3) and GBP1 (guanylate-binding protein 1)] in the urine of renal stone patients treated with ESWL, then we compared with healthy volunteers to evaluate their usefulness as diagnostic biomarkers for post ESWL kidney injury. The gene discussed is SBF2; the disease is medical procedure.